Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-6209 Combination Therapy in Breast Cancer
NCT06974929Phase 2Recruiting
- Sponsor
- Hengrui
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-6209 in breast cancer, sponsored by Hengrui. Started May 2025; status: recruiting.
02
Drugs
HRS-6209
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06974929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06974929.